🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 11 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/04/2013 105,19 106,54 104,74 105,88 +1,02% 1,71% 2.850.300
03/04/2013 106,68 106,79 103,93 104,81 -1,49% 2,68% 5.306.700
02/04/2013 102,39 106,61 102,39 106,40 +4,00% 4,12% 4.970.500
01/04/2013 102,62 103,90 101,70 102,31 -0,20% 2,14% 4.099.700
28/03/2013 99,84 102,62 99,79 102,51 +2,36% 2,83% 5.506.800
27/03/2013 98,06 100,32 98,02 100,15 +1,51% 2,35% 3.478.300
26/03/2013 97,29 98,76 97,07 98,66 +1,91% 1,74% 3.127.000
25/03/2013 96,92 97,52 96,01 96,81 +0,26% 1,56% 5.042.200
22/03/2013 94,69 96,60 94,10 96,56 +2,39% 2,64% 4.724.700
21/03/2013 93,65 94,31 93,47 94,31 +0,28% 0,90% 3.674.000
20/03/2013 92,92 94,89 92,88 94,05 +1,79% 2,16% 4.157.700
19/03/2013 90,68 92,52 90,54 92,40 +2,22% 2,18% 4.010.900
18/03/2013 91,27 91,36 90,35 90,39 -1,55% 1,11% 3.605.900
15/03/2013 91,84 92,16 91,26 91,81 -0,40% 0,98% 10.172.700
14/03/2013 91,65 92,29 91,15 92,18 +0,70% 1,24% 3.436.800
13/03/2013 91,60 91,79 90,67 91,54 -0,23% 1,22% 2.606.100
12/03/2013 91,58 91,81 91,04 91,75 +0,34% 0,84% 4.997.500
11/03/2013 92,66 93,36 90,87 91,44 -1,68% 2,69% 5.699.600
08/03/2013 93,43 93,88 92,85 93,00 +0,05% 1,10% 3.084.900
07/03/2013 93,43 93,88 92,82 92,95 -0,34% 1,13% 2.980.100
06/03/2013 93,82 94,29 93,09 93,27 -0,18% 1,28% 3.716.300
05/03/2013 93,11 93,76 92,56 93,44 +0,77% 1,29% 3.570.200
04/03/2013 92,11 92,75 91,50 92,73 +0,16% 1,36% 3.186.700
01/03/2013 91,16 92,76 90,51 92,58 +1,13% 2,47% 4.317.700
28/02/2013 91,00 93,42 90,87 91,55 +0,57% 2,80% 6.528.600
27/02/2013 89,15 91,30 89,06 91,03 +1,74% 2,51% 3.549.800
26/02/2013 89,63 90,21 88,66 89,47 -0,09% 1,73% 4.805.200
25/02/2013 89,30 91,25 89,30 89,55 +3,14% 2,18% 11.422.400
22/02/2013 85,07 86,88 85,07 86,82 +1,99% 2,13% 4.920.400
21/02/2013 84,59 85,32 84,15 85,13 +0,57% 1,38% 4.094.200